Research Compound Overview

AOD-9604: hGH Fragment (176-191) Research — Lipolysis, Adipocyte Metabolism & β3-Adrenergic Pathways

Last updated: July 2, 2026 · 15+ peer-reviewed studies referenced

AOD-9604 is a synthetic peptide corresponding to the C-terminal region of human growth hormone — residues 176-191 — with an additional N-terminal tyrosine, forming a 16-amino-acid hexadecapeptide. This fragment maps to the segment of the hGH molecule that early metabolic studies identified as carrying its lipolytic (fat-mobilizing) activity. The compound was developed specifically to isolate that fat-metabolism signal from the growth-promoting and metabolic actions of the full-length hormone. Across more than 15 peer-reviewed studies it has been characterized as a research tool for probing adipocyte metabolism, hormone-sensitive lipase and lipogenic enzyme activity, and β3-adrenergic pathway signaling.

What distinguishes AOD-9604 in fat-metabolism research is a dissociation of function: published work reports that the fragment reproduces aspects of growth hormone's effect on fat cells without engaging the growth hormone receptor itself. Because it does not activate that receptor, preclinical models find that it does not raise IGF-1 or drive the growth and glucose-metabolism effects associated with intact hGH — making it a useful probe for studying the lipolytic arm of GH signaling in isolation.

Chemical Profile

Primary Mechanisms of Action

1. Lipolysis Without GH-Receptor Activation

The defining mechanism documented in AOD-9604 research is stimulation of lipolysis — the breakdown of stored triglyceride in adipocytes — in the absence of growth hormone receptor engagement. Foundational metabolic studies of the synthetic lipolytic domain characterized how the fragment increases fat mobilization while, unlike intact hGH, not acting through the receptor that mediates growth and IGF-1 production. This separation is the central finding that frames the compound's use as a research probe.

In published models the lipolytic effect has been linked to increased activity of hormone-sensitive lipase (HSL), the enzyme that catalyzes triglyceride breakdown, together with a reduction in the activity of acetyl-CoA carboxylase, a key enzyme of fat synthesis. This dual read-out — favoring fat breakdown over fat storage at the enzyme level — appears repeatedly in the fragment's biochemical literature.

2. β3-Adrenergic Receptor Pathway

A distinctive theme in AOD-9604 research is its relationship to β3-adrenergic receptor (β3-AR) signaling, the adrenergic pathway most closely associated with fat oxidation and thermogenesis in adipose tissue. Preclinical work in obese and β3-AR knockout mouse models examined whether the fragment's metabolic effects depend on this pathway. The studies reported that the fragment could raise repressed β3-AR expression toward levels seen in lean animals, and that its metabolic activity was altered in animals lacking functional β3-AR.

This body of work positions β3-adrenergic signaling as a candidate mediator of the fragment's fat-metabolism effects, distinguishing its mechanism from the direct receptor engagement used by intact growth hormone. The β3-AR knockout data are among the most mechanistically informative in the compound's preclinical literature.

3. Fat Oxidation & Energy Balance

Beyond acute lipolysis, chronic-treatment studies in animal models examined the fragment's effect on whole-body fat oxidation and energy balance. Published research reported increases in measured fat oxidation and reductions in body-weight gain in obese-mouse models, accompanied by markers of increased lipolysis such as elevated plasma glycerol. Notably, these studies reported that the fragment achieved these metabolic read-outs without inducing the hyperglycemia associated with full-length hGH.

4. Separation from Growth & Glycemic Effects

A recurring point in the AOD-9604 literature is the absence of the growth and carbohydrate-metabolism effects seen with intact growth hormone. Because the fragment does not activate the GH receptor, published studies report that it does not raise IGF-1 levels and does not produce the insulin-resistance signal associated with hGH administration. This selectivity is the basis for its research interest as a tool for studying fat metabolism uncoupled from the somatotropic growth axis.

Research Applications

Adipocyte Metabolism Research

AOD-9604's principal research application is as a probe of adipocyte fat metabolism. Because it engages the lipolytic arm of growth hormone signaling while sparing the growth-receptor arm, it is used in the literature to study how fat breakdown and synthesis are regulated at the enzyme level — through hormone-sensitive lipase, acetyl-CoA carboxylase, and related pathways — independent of the confounding growth effects of intact hGH.

β3-Adrenergic Pathway Studies

The fragment appears in research on β3-adrenergic signaling in adipose tissue, where its dependence on this pathway has been examined in knockout models. This makes it a useful reference compound for studies dissecting how peptide signals interact with the adrenergic control of fat oxidation and thermogenesis.

Metabolic & Energy-Balance Models

In obese-animal models, AOD-9604 has been used to study fat oxidation, body-weight regulation, and lipid handling. Because it separates these metabolic read-outs from GH-receptor-driven growth and glycemic effects, it serves as a research tool for isolating the fat-metabolism component of growth hormone biology in energy-balance studies.

Cartilage & Connective-Tissue Research

A smaller area of the literature investigates AOD-9604 in connective-tissue models. Controlled animal studies have examined intra-articular administration of the fragment, alone or in combination with hyaluronic acid, in osteoarthritis models — extending research interest beyond adipose biology into cartilage and joint-tissue investigation.

Comparison with Full-Length Growth Hormone

AOD-9604 occupies a specific niche relative to intact human growth hormone. Where full-length hGH acts through the growth hormone receptor to drive IGF-1 production, tissue growth, and effects on carbohydrate metabolism, the fragment is characterized in the literature as reproducing only the lipolytic, fat-metabolism component while leaving the growth-receptor arm unengaged. This is the central distinction that defines its use as a research tool.

This dissociation of function also separates AOD-9604 from GH secretagogues such as GHRH analogs, which raise endogenous growth hormone and therefore engage the full spectrum of GH activity including IGF-1. The fragment, by contrast, models fat metabolism without amplifying the somatotropic axis — a complementary rather than overlapping position in peptide-metabolism research.

Research Limitations

While AOD-9604 has a well-defined preclinical mechanism, much of the foundational data derives from cell-culture systems and rodent models rather than large controlled human datasets. The available human safety literature is limited in scope, and findings from animal metabolic models should not be assumed to translate directly to other systems.

Additionally, because the fragment's effects appear to involve β3-adrenergic signaling and enzyme-level regulation of fat metabolism rather than a single defined receptor, attributing its activity to one discrete pathway remains difficult. The precise molecular target that mediates its lipolytic signal continues to be an area requiring further investigation.

Latest Studies

Curated from PubMed and peer-reviewed metabolic-research literature, ranked by journal tier and study type, and link-validated · updated July 2, 2026. Provided for research-use context only.